CA2831074A1 - Gene expression predictors of cancer prognosis - Google Patents

Gene expression predictors of cancer prognosis Download PDF

Info

Publication number
CA2831074A1
CA2831074A1 CA2831074A CA2831074A CA2831074A1 CA 2831074 A1 CA2831074 A1 CA 2831074A1 CA 2831074 A CA2831074 A CA 2831074A CA 2831074 A CA2831074 A CA 2831074A CA 2831074 A1 CA2831074 A1 CA 2831074A1
Authority
CA
Canada
Prior art keywords
expression
seq
sample
level
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2831074A
Other languages
English (en)
French (fr)
Inventor
Joshi Alumkal
Shannon K. Mcweeney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of CA2831074A1 publication Critical patent/CA2831074A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2831074A 2011-03-26 2012-03-23 Gene expression predictors of cancer prognosis Abandoned CA2831074A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161467999P 2011-03-26 2011-03-26
US61/467,999 2011-03-26
PCT/US2012/030309 WO2012135008A1 (en) 2011-03-26 2012-03-23 Gene expression predictors of cancer prognosis

Publications (1)

Publication Number Publication Date
CA2831074A1 true CA2831074A1 (en) 2012-10-04

Family

ID=46931859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2831074A Abandoned CA2831074A1 (en) 2011-03-26 2012-03-23 Gene expression predictors of cancer prognosis

Country Status (5)

Country Link
US (2) US20140113297A1 (enExample)
EP (1) EP2691547A4 (enExample)
JP (1) JP2014509868A (enExample)
CA (1) CA2831074A1 (enExample)
WO (1) WO2012135008A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
EP2591126B1 (en) 2010-07-07 2020-12-30 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
JP2015522277A (ja) * 2012-06-28 2015-08-06 カルドラ ヘルス リミテッドＣａｌｄｅｒａ Ｈｅａｌｔｈ Ｌｔｄ 前立腺癌の診断方法と診断用物質
AU2013302365B2 (en) 2012-08-16 2019-03-21 Mayo Foundation For Medical Education And Research Cancer diagnostics using biomarkers
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
EP2971177B1 (en) * 2013-03-14 2019-09-11 Neogenomics Laboratories, Inc. Compositions and methods for detecting and determining a prognosis for prostate cancer
WO2014159443A1 (en) * 2013-03-14 2014-10-02 Genomedx Biosciences, Inc. Cancer biomarkers and classifiers and uses thereof
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2017062505A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
CA3050984A1 (en) 2017-01-20 2018-07-26 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
US11083127B2 (en) 2018-05-09 2021-08-10 Deere & Company Seeding machine to provide transverse tramlines
US20230323466A1 (en) * 2020-07-15 2023-10-12 Queensland University Of Technology Determining cancer responsiveness to treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
US7914988B1 (en) * 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
WO2008021290A2 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
US8470534B2 (en) * 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
CA2725978A1 (en) * 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
CA2730277A1 (en) * 2008-07-08 2010-01-14 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for predicting the survivability of prostate cancer subjects
EP3118328A1 (en) * 2009-01-07 2017-01-18 Myriad Genetics, Inc. Cancer biomarkers
WO2010129965A1 (en) * 2009-05-08 2010-11-11 The Regents Of The University Of California Cancer specific mitotic network
CA2776751C (en) * 2009-11-23 2019-07-02 Genomic Health, Inc. Methods to predict clinical outcome of cancer
EP2591126B1 (en) * 2010-07-07 2020-12-30 Myriad Genetics, Inc. Gene signatures for cancer prognosis

Also Published As

Publication number Publication date
EP2691547A4 (en) 2015-01-14
US20140113297A1 (en) 2014-04-24
US20160168649A1 (en) 2016-06-16
JP2014509868A (ja) 2014-04-24
EP2691547A1 (en) 2014-02-05
WO2012135008A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
US20160168649A1 (en) Gene expression predictors of cancer prognosis
RU2654587C2 (ru) Способ предсказания рецидива рака молочной железы при эндокринном лечении
US9758829B2 (en) Molecular malignancy in melanocytic lesions
KR101562644B1 (ko) 직장결장암용 예후 예측
US20200248269A1 (en) Methods for predicting the outcome of a cancer in a patient by analysing gene expression
JP2017532959A (ja) Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
US20110143946A1 (en) Method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
CA2726531A1 (en) Compositions and methods for classifying lung cancer and prognosing lung cancer survival
JP2017508442A (ja) Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー
EP2460005A1 (en) Methods of assessing a risk of cancer progression
JP2009148269A (ja) 微量胃癌細胞の検出法
US20160222461A1 (en) Methods and kits for diagnosing the prognosis of cancer patients
US11840733B2 (en) Method for predicting prognosis of breast cancer patient
GB2616359A (en) Methods and genomic classifiers for identifying homologous recombination deficiency prostate cancer
WO2005076005A2 (en) A method for classifying a tumor cell sample based upon differential expression of at least two genes
WO2020051293A1 (en) Recurrence gene signature across multiple cancer types
US8747867B2 (en) Cancer markers
WO2013172947A1 (en) Method and system for predicting recurrence and non-recurrence of melanoma using sentinel lymph node biomarkers
EP2716767A1 (en) Method for determining the prognosis of pancreatic cancer
JP2006223303A (ja) 微量胃癌細胞の検出法
JP2006166789A (ja) 癌の新規診断方法
US20160273045A1 (en) Methods of determining breast cancer prognosis
WO2022196750A1 (ja) 子宮体がんのリンパ節転移能の評価方法のためのコンパニオンマーカー
WO2008125791A1 (en) Cancer markers
EP2531856A2 (en) Methods and kits used in classifying adrenocortical carcinoma

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180323